Central Nervous System
This refresher course lecture on adult central nervous system tumors will provide a framework for understanding the classification of brain tumors including newer molecular diagnostics for gliomas. Using that framework, we will review literature with an emphasis on new publications on treatment options for patients with adult central nervous system tumors. Topics to be covered include gliomas, brain metastases, and benign brain tumors.
Target Audience
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this live activity, attendees should be able to do the following:
1. Understand with how glioma treatment is shaped by new molecular diagnostics.
2. Identify the pros/cons of approaches to brain metastases treatments including multifraction stereotactic radiosurgery, hippocampal sparing whole brain RT, and stereotactic radiosurgery for multiple brain metastases.
3. Recognize the response of brain metastases to new systemic therapy agents.
Stephanie Weiss, MD, FASTRO is employed by Fox Chase Cancer Center and has no other disclosures to declare.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 2.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 2.00 Certificate of AttendanceThis activity was designated for 2.00 AMA PRA Category 1 Credit™.